Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase 4 or 2 (Nox4 or Nox2) activity. A pharmaceutical composition comprising the compound.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Abstract: The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine or a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase activity. A pharmaceutical composition comprising the compound.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Abstract: The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidaseactivity. A pharmaceutical composition comprising the compound.

Abstract: A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Abstract: A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Abstract: A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Abstract: The invention relates to a method for treatment of obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus by administering a drug capable of modulating the regulation of UCP-2, the use of a drug capable of modulating the regulation of UCP-2 for the production of drug for treatment of obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus and pharmaceutical composition comprising a pharmaceutically effective amount of such a drug. The invention is also related to methods for screening for potential drugs against obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus and the use of cDNA probe for determination of upregulation of UCP-2 for potential drugs against obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus.

Abstract: A process is presented for reducing the detrimental influence of certain proteases on recombinant human protein and polypeptide production in a cell culture, which comprises adding an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium. The cell culture medium for cultivating cells expressing and secreting a biologically active recombinant human polypeptide contains an inhibitor of metal-dependent proteases or chymotrypsins, or a combination thereof. Recombinant factor VIII which has been produced in a cell culture medium according to the present process is useful for the manufacture of a medicament for administration to a patient having the symptoms of hemophilia A and for treatment of hemophilia A by administration of a therapeutically effective amount of recombinant factor VIII.

Abstract: The invention aims at replacing animal experiments for determining acute toxicity (LD.sub.50 values) by utilizing stable perfusion-cultivated cell cultures and also at producing a cultivation chamber which is movable during operation, for determining various parameters.